Genmab — Februar 2020
-
God morgen.

-
U.S. FDA Filing Acceptance and Priority Review for sBLA, Submitted by Novartis, for Ofatumumab in Relapsing Multiple Sclerosis
-
Novartis anticipates potential regulatory approval in the U.S. in June 2020
-
Marketing Authorization Application for ofatumumab in RMS also accepted for review by EMA with potential regulatory approval anticipated by Novartis by the second quarter of 2021
-
Gode nyheder Jeps.
-
L
idt positivt nyt fra Kina (hvis det holder vand?)Recovery's big numbers
Confirmed cases sinking
Deaths should be at Peak or on the way down
New numbers, confirming
peak virus may have happened in early February.
https://twitter.com/MilesTaylor47/status/1231761318878699525
-
Spørgsmål til Q&A er meget velkommen.
-
Genmab holder pharma-fanen højt i dag.
-
Jeg kan slet ikke se Play på forsiden af Børsen (toplinjen).
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind